[iNtRON] Files U.S. Patent for Three Novel Endolysin-Based Drug Candidates Targeting Gram-Negative Bacteria Provided by PR Newswire Jul 2, 2025, 5:00:00 AM ...

Findings This mutation involves the deletion of an adenine in intron 11 that abolishes the canonical splice acceptor site of exon 12 (Perrone et al., 2018). This leads to exon 12 skipping and a ...

Massachusetts Institute Of Technology. "Researchers Shed Light On Intron Evolution." ScienceDaily. ScienceDaily, 27 December 2004. <www.sciencedaily.com / releases / 2004 / 12 / 041219165202.htm>.

Intron’s key semiconductor supplier, Infineon, could also change distributors and it would take Intron time to learn about the semiconductors from a new supplier and redo its key designs.

iNtRON Biotechnology, Inc., a biotechnology company focused on developing innovative endolysin-based new biological drug for superbugs and unmet medical needs, today announced the strategic ...

Intron Biotechnology Inc. has announced the identification of lysogenic bacteriophages prophage and jamphage in the pancreatic cancer-related microbiome. This identification was achieved as part of ...

China-based automotive electronics provider Intron Technology has partnered with eSOL, a developer of real-time embedded software solutions, to advance the development of next-generation software ...

INTRON A SOLN prescription and dosage information for physicians and health care professionals. Pharmacology, adverse reactions, warnings, and INTRON A SOLNside effects.